临床外科杂志 ›› 2020, Vol. 28 ›› Issue (8): 764-766.doi: 10.3969/j.issn.1005-6483.2020.08.021

• • 上一篇    下一篇

麦默通旋切术用于乳腺癌病灶切除的临床价值

  

  1. 100006 首都医科大学附属北京妇产医院乳腺科
  • 出版日期:2020-08-20 发布日期:2020-08-20
  • 通讯作者: 王钢乐,Email:gangyue_wang@163.com

The clinical value of ultrasound-guided Mammotomein for the resection of breast cancer lesions

  1. Department of Breast Surgery,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100006,China
  • Online:2020-08-20 Published:2020-08-20

摘要: 目的  探讨麦默通旋切术(Mammotome,MMT)用于乳腺癌病灶切除的临床价值。
方法  接受超声引导下MMT,术后病理检查确诊为乳腺癌,并接受再次开放手术病人75例,根据MMT后有无肿瘤残留分为肿瘤残留组和肿瘤无残留两组,肿瘤残留组39例,肿瘤无残留组36例。分析乳腺癌肿瘤病灶残留与临床、病理因素间的关系。
结果  乳腺癌MMT后肿瘤病灶残留率为52.0%。年龄、组织学类型、Ki-67表达与乳腺癌肿瘤病灶残留相关(P<0.05);年龄是乳腺癌肿瘤病灶残留的独立危险因素,P<0.05。
结论  乳腺癌经超声引导下MMT切除肿瘤病灶,肿瘤残留率偏高。不建议应用MMT治疗乳腺癌。

关键词: 乳腺癌, 麦默通, 病灶残留

Abstract: Objective To investigate clinical value of ultrasound-guided Mammotome(MMT)in the treatment of breast cancer.
Methods The clinical data of 75 patients with MMT and reoperation were collectedin the treatment of breast cancer.According to whether there was residual tumor after MMT,patients were divided into residual tumor group(39 cases)and non-residual group(36 cases).The relationship of residual tumorsand clinical and pathological factors between two groups was compared.
Results The rate of residuallesions after MMT was 52.0%,The residual lesionswere closely related to patient age,tumor differentiation,Ki-67expression(P<0.05);patient age was an independent risk factor for residual breast tumor(P<0.05).
Conclusion There was a high rate of residual tumors after MMT in breast cancer.MMT is not recommended for breast cancer.

Key words: breast cancer, Mammotome(MMT), residual tumor

[1] 郑丽华 吴尚 张晶 张泽鹏 王昕仪 杨天硕 赵亚恒 贺新奇 刘运江. 纤维蛋白原与三阴性乳腺癌总生存期的关系[J]. 临床外科杂志, 2020, 28(8): 767-770.
[2] 于永政, 梁雪妍, 邢娴娴等. 乳腺癌荧光染料法腋窝反向淋巴作图的可行性及安全性研究[J]. 临床外科杂志, 2020, 28(6): 551-553.
[3] 闾志坚 曹玉根 李耀. 不同年龄段三阴性乳腺癌病人临床病理特征与预后的相关性研究[J]. 临床外科杂志, 2020, 28(3): 250-253.
[4] 王祥军. 核仁蛋白、Ki-67表达对乳腺癌病人病情发生发展的影响分析[J]. 临床外科杂志, 2020, 28(3): 273-275.
[5] 林锦娜, 刘强. 2019年NCCN乳腺癌临床实践指南更新解读:乳腺癌局部治疗新进展[J]. 临床外科杂志, 2020, 28(1): 27-30.
[6] 吴晓琴, 邹丽, 胡慧, 钟洁愉, 刘晓岭, 孙德胜, 韦伟. 术前超声造影联合细胞学检查判断乳腺癌前哨淋巴结状态122例分析[J]. 临床外科杂志, 2020, 28(1): 49-52.
[7] 周萍, 许楠, 陆澄. 腋窝淋巴结状态对乳腺癌保乳手术后复发病人的预后影响[J]. 临床外科杂志, 2019, 27(9): 769-772.
[8] 杨丽君. 麦默通微创旋切术在治疗乳腺良性肿瘤中的疗效与价值[J]. 临床外科杂志, 2019, 27(8): 703-704.
[9] 祝景伟, 许培权. 乳腺癌肉瘤一例[J]. 临床外科杂志, 2019, 27(8): 730-730.
[10] 陈志超, 王杰芳. 乳腺癌手术切口皮肤缝合器与丝线间断缝合的对比分析[J]. 临床外科杂志, 2019, 27(4): 289-290.
[11] 徐玲, 刘荫华. 乳腺癌国际指南与中国临床实践[J]. 临床外科杂志, 2019, 27(3): 181-182.
[12] 范威, 吴新红. 乳腺癌新辅助化疗后手术时机的选择[J]. 临床外科杂志, 2019, 27(3): 183-186.
[13] 李颖, 刘强. 乳腺癌的免疫治疗进展[J]. 临床外科杂志, 2019, 27(3): 187-189.
[14] 曹旭晨. 乳腺癌保乳之中国经验[J]. 临床外科杂志, 2019, 27(3): 190-192.
[15] 陈香蓉, 权毅, 付华, 梁华. 多灶性多中心性乳腺癌癌灶间异质性及其对治疗决策的影响分析[J]. 临床外科杂志, 2019, 27(3): 197-200.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!